Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Change in Accured Expenses: 2013-2020

Historic Change in Accured Expenses for Larimar Therapeutics (LRMR) over the last 7 years, with Dec 2020 value amounting to $2.5 million.

  • Larimar Therapeutics' Change in Accured Expenses rose 475.97% to $2.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was $3.2 million, marking a year-over-year increase of 242.01%. This contributed to the annual value of $13.4 million for FY2024, which is 1414.68% up from last year.
  • Larimar Therapeutics' Change in Accured Expenses amounted to $2.5 million in Q4 2020, which was up 811.58% from -$354,000 recorded in Q3 2020.
  • Larimar Therapeutics' 5-year Change in Accured Expenses high stood at $2.5 million for Q4 2020, and its period low was -$1.7 million during Q2 2016.
  • Over the past 3 years, Larimar Therapeutics' median Change in Accured Expenses value was $462,500 (recorded in 2018), while the average stood at $400,417.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 499.24% in 2018, then soared by 475.97% in 2020.
  • Larimar Therapeutics' Change in Accured Expenses (Quarterly) stood at -$843,000 in 2016, then spiked by 240.57% to $1.2 million in 2017, then slumped by 140.51% to -$480,000 in 2018, then crashed by 39.58% to -$670,000 in 2019, then skyrocketed by 475.97% to $2.5 million in 2020.
  • Its Change in Accured Expenses stands at $2.5 million for Q4 2020, versus -$354,000 for Q3 2020 and $837,000 for Q2 2020.